PropThink
Contributor since: 2012
Company: PropThink
Latest Articles
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock
An Encouraging Quarter, Ironwood One To Keep On The Radar In 2014
The Market Just Isn't Convinced The AVEO Nightmare Is Over
Drugs That Disappointed Investors In 2013: Infinity's IPI-145
Albany Molecular Aspires To Grow Revenue Five-Fold In As Many Years
Next Chapter In The Acorda Story Will Be A Page Turner
Emergent BioSolutions Is Building An Enviable BioDefense Portfolio
On Sarepta's 2013 Results And Upcoming Events
Investors Are Coming Back Around On XenoPort
Cempra: Safety Results Solidifying Market Position
Professional Investor Explains His 2 Largest Healthcare Holdings
BioLife Solutions' Uplisting, Debt Deal Provide Overlooked Opportunity
Pharmacyclics: As Imbruvica Commercialization Begins, Sell-Off Creates Opportunity
A Glance At Our Winners And Losers In 2013
Understanding Zerenex's Patent Protection And Latest Issuance
Cubist Set For A Solid 2014 With Pipeline Progress
BioDelivery Sciences: Delivering Profits In 2014
'Greed Is Good': Hologic Attracts The Value Crowd
Canadian Acquisitions: QLT Inc. Fits The Trend
This Antibiotic Play May Be The Trius Of 2014
The Long Case For Zogenix
Why Doctors, Dialysis Providers And Investors Are Excited About Zerenex
The Market Is Missing Pozen's Potential Cash Distribution And Upcoming Approval
ViroPharma's Core Business Is Accelerating, New Opportunities Emerge
Data Support Keryx's Anemia Drug In A New And Large Market
Risk/Reward Remains Positive For Durect
Cash, Catalysts And Charisma Should Drive Neuralstem Well Above $3
What Shutdown? Illumina Rises Above The Noise
Zalicus: An Upcoming Catalyst With Huge Potential
Why Zerenex Could Be More Than Just A Dialysis Product
BIND Therapeutics Had A Muted IPO But The Thesis Intrigues
Things Just Got A Little Brighter For Vivus